[1] Dafni UG, Tzioufas AG, Staikos P, et al. Prevalence of SjÖgren’s syndrome in a closed rural community[J]. Ann Rheum Dis, 1997, 56(9): 521-525.
[2] Thomas E, Hay EM, Hajeer A, et al. SjÖgren’s syndrome: a community-based study of prevalence and impact[J]. Br J Rheumatol, 1998, 37(10): 1069-1076.
[3] Voulgarelis M, Dafni UG, Isenberg DA, et al. Malignant lymphoma in primary SjÖgren’s syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sj?gren’s syndrome[J]. Arthritis Rheum, 1999, 42(8): 1765-1772.
[4] Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17[J]. Nat Immunol, 2005, 6(11): 1133-1141.
[5] Willeke P, Schotte H, Schulter B, et al. Interleukin 1 beta and tumor necrosis factor alpha secreting cells are increased in the peripheral blood of patients with primary SjÖgren’s syndrome [J]. Ann Rheum Dis, 2003, 62(4): 359-362.
[6] Garcic-Carrasco M, Font J, Filella X, et al. Circulating levels of TH1/Th2 cytokines in patients with primary Sj?gren’s syndrome: correlation with clinical immunological features[J]. Clin Exp Rheumatol, 2001, 19(4): 411-415.
[7] Azuma M, Motegi K, Aota K, et al. Role of cytokines in the destruction of acinar structure in SjÖgren’s syndrome salivary glands[J]. Lab Invest, 1997, 77(3): 269-280.
[8] Zoukhri D, Hodges RR, Byon D, et al. Role of proinflammatory cytokines in the impaired lacrimation associated with autoimmune xerophthalmia[J]. Invest Ophthalmol Vis Sci, 2002, 43(5): 1429-1436.
[9] Tornwald J, Fox H, Edward C, et al. Treatment with pegylated recombinant methionyl human soluble tumor necrosis factor-type1 receptor (PEG sTNF-R1) prevents development of SjÖgren’s syndrome and diabetes in the NOD mouse model[J]. Arthritis Rheum, 1999, 42(Suppl 9): S403-407.
[10] Peacock DJ, Banquerigo ML, Brahn E. Angiogenesis inhibition suppresses collagen arthritis[J]. J Exp Med, 1992, 175(4): 1135-1138.
[11] Shinohara ML, Lu L, Bu J, et al. Osteopontin expression is essential for IFN-a production by plasmacytoid dendritic cells[J]. Nat Immunol, 2006, 7(5): 498-506.
[12] Hur EM, Youssef S, Haws ME, et al. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells[J]. Nat Immunol,2007,8(1), 74-83.
[13] Shinohara ML, Kim HJ, Kim JH, et al. Alternative translation of osteopontin generates intracellular and secreted isoforms that mediate distinct biological activities in dendritic cells[J]. Proc Natl Acad Sci USA , 2008, 105(20): 7235-7239.
[14] Cantor H, Shinohara ML. Regulation of T-helper-cell lineage development by osteopontin: the inside story[J]. Nat Rev Immunol, 2009, 9(2): 137-141.
[15] Murugaiyan G, Mittal A, Weiner HL. Identification of an IL-27/osteopontin axis in dendritic cells and its modulation by IFN-γ limits IL-17-mediated autoimmune inflammation[J]. Proc Natl Acad Sci USA, 2010, 107(25): 11495-11500. |